Bio­gen vet jumps to CSO at Third Rock Treg biotech; Karuna CEO is step­ping down, but this is­n't good­bye

Just a few days in­to her new job, Ellen Cahir-Mc­Far­land’s of­fice is be­ing emp­tied.

Cahir-Mc­Far­land, for­mer­ly head of re­search at An­nex­on, is the new chief sci­en­tif­ic of­fi­cer of Aba­ta Ther­a­peu­tics, a pre­clin­i­cal biotech that’s de­vel­op­ing reg­u­la­to­ry T cell, or Treg, ther­a­pies for mul­ti­ple scle­ro­sis. On Mon­day, Aba­ta will be mov­ing from its cur­rent shared space to its new of­fice in Wa­ter­town, MA — hence the emp­ty­ing, Cahir-Mc­Far­land tells End­points News from a now bare, white-walled of­fice room.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.